Daniel P. Gold PhD - 29 Sep 2023 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Reporting relationship: Director
Issuer ticker: MEIP
Reported as of: 29 Sep 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Oct 2023, 19:41:09 UTC
Prior SEC filing: 07 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ David M. Urso, as attorney in fact

Key filing fact

Daniel P. Gold PhD filed Form 4 for MEI Pharma, Inc. (MEIP) on 12 Oct 2023.

Key facts

This page summarizes Daniel P. Gold PhD's Form 4 filing for MEI Pharma, Inc. (MEIP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Oct 2023, 19:41.

Change

Previous filing in this sequence was filed on 07 Jul 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MEIP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +10,000
Change %
Price: $0.000000
Shares after: 10,000
Date: 29 Sep 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $7.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Such option shall vest as follows: 16.66666% shall be vested on the date of grant, and the remaining shares subject to the option shall vest in equal monthly amounts beginning October 1, 2023 and continuing on the first day of each calendar month following such date and continuing through July 1, 2024.